Novo Nordisk Targets Teenage Diabetes Patients as Pipeline Data Looms

Novo Nordisk targets paediatric diabetes with Rybelsus/Ozempic filings, while CagriSema phase-3 results at ADA could shape its next growth wave. Stock down 13.8% YTD.

Novo Nordisk is gearing up for a busy second half of 2026, balancing an ambitious push into paediatric diabetes care with a pivotal data dump from its pipeline. The Danish drugmaker plans to file regulatory applications in both the US and the EU for Rybelsus and oral Ozempic in patients aged 10 to 17 with type-2 diabetes. Those submissions, expected later this year, are designed to lock in long-term market share in a segment where Novo already commands a global volume share of 54.6% across diabetes and obesity.

That paediatric offensive runs in parallel with a high-stakes scientific showcase at the American Diabetes Association’s annual meeting in New Orleans. Novo Nordisk will present 40 abstracts at the conference, which runs from 5 to 8 June. The headline act falls on the evening of 7 June, when the company unveils phase-3 data from the REIMAGINE-1, -2 and -3 trials of CagriSema, a combination of an amylin analogue and GLP-1. The studies examine how the dual therapy affects blood sugar control and weight loss in type-2 diabetes patients already on different baseline treatments. Phase-2 results for Zenagamtid, a once-weekly GLP-1/amylin combination, are also on the agenda.

Alongside the pipeline event, the company has been beefing up its manufacturing firepower. Following the closure of its Catalent acquisition in December 2024, Novo Nordisk integrated three additional production sites, sharply expanding its fill-finish capacity. The extra lines are intended to ease earlier supply bottlenecks and support the launch of new formulations, including a higher 25-mg dose of oral Ozempic for adults. A decision on that application is also due in the second half of 2026. The company’s oral Wegovy pill, approved for obesity and cardiovascular disease at the end of 2025, has already attracted more than a million new users in the US within four months of launch.

On the financial front, Novo Nordisk’s stock is trading at around €38.51, 13.8% lower than where it started the year and a far cry from its 2026 peak of €70.13. The forward price-to-earnings ratio stands at 12.80, below that of main rival Amgen at 14.76. A share buyback programme worth up to DKK 15bn has been running since February, with the company holding roughly 34.2 million B-shares, or about 0.8% of total capital, at the end of May.

First-quarter results painted a mixed picture. Reported revenues climbed 24% to DKK 96.8bn, and operating profit surged 54%. Strip out a one-off item in the US business, however, and adjusted net revenues fell 10% to DKK 70.1bn, while adjusted operating profit dropped 15%. Management raised its full-year guidance but still expects both metrics to decline by 4% to 12%.

With the ADA conference acting as a litmus test for the next generation of growth drivers — CagriSema and Zenagamtid — investor attention will shift away from capital returns and regulatory headlines focused on Wegovy. The company has scheduled an R&D investor event for 7 June, followed by half-year results on 5 August. For Novo Nordisk, the science presented in New Orleans will set the tone for a year that could redefine its pipeline narrative as much as its commercial expansion into younger patients.